Miriplatin

Miriplatin is a chemotherapy drug used in the treatment of hepatocellular carcinoma, a type of liver cancer. It is a platinum-based compound that is administered via hepatic artery infusion, a method that delivers the drug directly to the tumor.

Mechanism of Action[edit | edit source]

Miriplatin works by interfering with the DNA of cancer cells, preventing them from dividing and growing. It forms covalent bonds with the DNA, causing it to become cross-linked and unable to separate. This prevents the DNA from being replicated, which in turn stops the cancer cells from dividing and multiplying.

Administration[edit | edit source]

Miriplatin is administered via hepatic artery infusion. This method involves inserting a catheter into the hepatic artery, which supplies blood to the liver. The drug is then infused directly into the artery, allowing it to reach the tumor more effectively. This method also helps to minimize the side effects of the drug, as it is not distributed throughout the entire body.

Side Effects[edit | edit source]

Like all chemotherapy drugs, miriplatin can cause side effects. These can include nausea, vomiting, fatigue, and hair loss. More serious side effects can include liver damage, kidney damage, and neutropenia, a condition characterized by a low number of white blood cells.

Clinical Trials[edit | edit source]

Miriplatin has been studied in several clinical trials. These studies have shown that it can be effective in treating hepatocellular carcinoma, particularly in patients who have not responded to other treatments. However, more research is needed to determine the optimal dosage and administration schedule.